| STATUS |
has been evaluated in four Phase 2 efficacy studies enrolling more than 300 men. Phase 2 data was presented at the American Urological Association meeting in May 2003. Data from the Phase 2 at-home study was presented at the 8th Annual Leadership Conference on Sexual, Cardiovascular and Metabolic Syndrome Related Therapies in November 2003. The Company plans to begin Phase 3 trials in men in late 2006. Key Clinical Findings from Phase 2 Studies: effective in a broad range of patients, including those with severe ED and those non-responsive to sildenafil efficacy in at-home studies is comparable to PDE-5 inhibitors up to 50% of ED patients were restored to a normal level of function co-administration with sildenafil shows superior efficacy side effects included: facial flushing nausea aftertaste post-nasal drip |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |